Akhila Balasubramanian1, Laura L Tosi2, Joseph M Lane3, Douglas R Dirschl4, Pei-Ran Ho5, Cynthia D O'Malley6. 1. Center for Observational Research, Amgen Inc., One Amgen Center Drive, MS 24-2-A, Thousand Oaks, CA 91320. 2. Children's National Medical Center, Attn: Orthopedics, 111 Michigan Avenue NW, Washington DC 20010. 3. Weill Cornell Medical College, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021. 4. Department of Orthopaedics, University of North Carolina at Chapel Hill School of Medicine, 3147 Bioinformatics Building, Campus Box 7055, Chapel Hill, NC 27599-7055. 5. Clinical Development, Amgen Inc., One Amgen Center Drive, MS 27-5-A, Thousand Oaks, CA 91320. 6. Center for Observational Research, Amgen Inc., 1120 Veterans Boulevard, MS ASF2, South San Francisco, CA 94080. E-mail address for C.D. O'Malley: comalley@amgen.com.
Abstract
BACKGROUND: Clinical practice recommendations state that patients with fragility fractures should be evaluated for osteoporosis and treated for the disease if it is present. The purpose of this study was to assess osteoporosis evaluation and treatment patterns for patients with fragility fractures and assess whether anti-osteoporosis pharmacotherapy initiated immediately following a fragility fracture is associated with improved adherence to the treatment protocol. METHODS: This retrospective cohort study involved data from a large commercially insured population seen in the period from 2001 through 2009. Patients were community-dwelling individuals aged fifty years or older who had a new low-energy fracture at the hip, vertebra, wrist, or humerus with no evidence of a fragility fracture, osteoporosis treatment, malignant disease, or Paget disease for twelve months preceding the fracture. Rates of diagnostic testing and pharmacotherapy for osteoporosis within twelve months post-fracture were evaluated. Patients treated with oral bisphosphonates were evaluated to determine whether twelve-month adherence to the treatment protocol differed between those who had initiated therapy sooner (at zero to ninety days) and those who initiated it later (at ninety-one to 365 days) following the fracture. RESULTS: The 88,571 women and 41,984 men had an average age of 72.3 years and 70.5 years, respectively. Nineteen percent (16,464) of the women and 10% (4014) of the men initiated osteoporosis pharmacotherapy, and 30% (26,481) of the women and 15% (6427) of the men underwent diagnostic testing and/or pharmacotherapy following fracture. Treatment rates were highest following vertebral fracture and lowest following wrist or humeral fracture. Treatment rates significantly decreased over time (from 2001 through 2009). The average twelve-month adherence (medication possession ratio) was 56% and 61% among women and men, respectively. Adherence was similar between patients who had initiated treatment sooner after the fracture and those who had initiated it later after the fracture. CONCLUSIONS: Clinical guidelines for evaluation and treatment following fragility fracture were met for less than one-third of women and less than one-sixth of men. While primary fracture prevention remains the ideal, secondary prevention is critical and there is a need to reverse the downward trend in adherence to post-fracture guidelines.
BACKGROUND: Clinical practice recommendations state that patients with fragility fractures should be evaluated for osteoporosis and treated for the disease if it is present. The purpose of this study was to assess osteoporosis evaluation and treatment patterns for patients with fragility fractures and assess whether anti-osteoporosis pharmacotherapy initiated immediately following a fragility fracture is associated with improved adherence to the treatment protocol. METHODS: This retrospective cohort study involved data from a large commercially insured population seen in the period from 2001 through 2009. Patients were community-dwelling individuals aged fifty years or older who had a new low-energy fracture at the hip, vertebra, wrist, or humerus with no evidence of a fragility fracture, osteoporosis treatment, malignant disease, or Paget disease for twelve months preceding the fracture. Rates of diagnostic testing and pharmacotherapy for osteoporosis within twelve months post-fracture were evaluated. Patients treated with oral bisphosphonates were evaluated to determine whether twelve-month adherence to the treatment protocol differed between those who had initiated therapy sooner (at zero to ninety days) and those who initiated it later (at ninety-one to 365 days) following the fracture. RESULTS: The 88,571 women and 41,984 men had an average age of 72.3 years and 70.5 years, respectively. Nineteen percent (16,464) of the women and 10% (4014) of the men initiated osteoporosis pharmacotherapy, and 30% (26,481) of the women and 15% (6427) of the men underwent diagnostic testing and/or pharmacotherapy following fracture. Treatment rates were highest following vertebral fracture and lowest following wrist or humeral fracture. Treatment rates significantly decreased over time (from 2001 through 2009). The average twelve-month adherence (medication possession ratio) was 56% and 61% among women and men, respectively. Adherence was similar between patients who had initiated treatment sooner after the fracture and those who had initiated it later after the fracture. CONCLUSIONS: Clinical guidelines for evaluation and treatment following fragility fracture were met for less than one-third of women and less than one-sixth of men. While primary fracture prevention remains the ideal, secondary prevention is critical and there is a need to reverse the downward trend in adherence to post-fracture guidelines.
Authors: Gulsen Ozen; Diane L Kamen; Ted R Mikuls; Bryant R England; Frederick Wolfe; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2018-03-11 Impact factor: 4.794
Authors: Seoyoung C Kim; Mi-Sook Kim; Gabriel Sanfélix-Gimeno; Hong Ji Song; Jun Liu; Isabel Hurtado; Salvador Peiró; Joongyub Lee; Nam-Kyong Choi; Byung-Joo Park; Jerry Avorn Journal: Am J Med Date: 2015-02-03 Impact factor: 4.965
Authors: Christopher Sciamanna; Noel H Ballentine; Melissa Bopp; Jennifer S Brach; Vernon M Chinchilli; Joseph T Ciccolo; Molly B Conroy; Abigail Fisher; Edward J Fox; Susan L Greenspan; M Jan De Beur Suzanne; Kalen Kearcher; Jennifer L Kraschnewski; Kathleen M McTigue; Edward McAuley; Natalia E Morone; Anuradha Paranjape; Sol Rodriguez-Colon; Andrew Rosenzweig; Joshua M Smyth; Kerry J Stewart; Heather L Stuckey Journal: Contemp Clin Trials Date: 2018-09-24 Impact factor: 2.226